CC-220 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 7 |
49. 全身性エリテマトーデス
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-004574-17-FR (EUCTR) | 30/11/2017 | 28/11/2018 | A study to measure how safe CC-220 is and how well CC-220 works in people with lupus. | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | SYSTEMIC LUPUS ERYTHEMATOSUS MedDRA version: 20.0;Level: LLT;Classification code 10025134;Term: Lupus erythematosus;System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 | Celgene Corporation | NULL | Not Recruiting | Female: yes Male: yes | 280 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Serbia;United States;Spain;Russian Federation;Colombia;Italy;France;Hungary;Mexico;Canada;Argentina;Belgium;Brazil;Poland;Germany | ||
| 2 | EUCTR2016-004574-17-BE (EUCTR) | 14/11/2017 | 07/06/2017 | A study to measure how safe CC-220 is and how well CC-220 works in people with lupus. | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | SYSTEMIC LUPUS ERYTHEMATOSUS MedDRA version: 20.0;Level: LLT;Classification code 10025134;Term: Lupus erythematosus;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 | Celgene Corporation | NULL | Not Recruiting | Female: yes Male: yes | 280 | Phase 2 | United States;Serbia;Spain;Russian Federation;Colombia;Italy;France;Hungary;Mexico;Canada;Argentina;Belgium;Brazil;Poland;Germany | ||
| 3 | EUCTR2016-004574-17-DE (EUCTR) | 27/09/2017 | 21/04/2017 | A study to measure how safe CC-220 is and how well CC-220 works in people with lupus. | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | SYSTEMIC LUPUS ERYTHEMATOSUS MedDRA version: 20.0;Level: LLT;Classification code 10025134;Term: Lupus erythematosus;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 | Celgene Corporation | NULL | Not Recruiting | Female: yes Male: yes | 280 | Phase 2 | United States;Serbia;Spain;Russian Federation;Colombia;Italy;France;Hungary;Mexico;Canada;Argentina;Belgium;Brazil;Poland;Germany | ||
| 4 | NCT03161483 (ClinicalTrials.gov) | July 6, 2017 | 18/5/2017 | A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | Lupus Erythematosus, Systemic | Drug: CC-220;Other: Placebo | Celgene | NULL | Active, not recruiting | 18 Years | N/A | All | 289 | Phase 2 | United States;Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain |
| 5 | EUCTR2016-004574-17-HU (EUCTR) | 19/06/2017 | 13/04/2017 | A study to measure how safe CC-220 is and how well CC-220 works in people with lupus. | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | SYSTEMIC LUPUS ERYTHEMATOSUS MedDRA version: 21.1;Level: LLT;Classification code 10025134;Term: Lupus erythematosus;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 | Celgene Corporation | NULL | Not Recruiting | Female: yes Male: yes | 280 | Phase 2 | Serbia;United States;Spain;Russian Federation;Colombia;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Belgium;Poland;Germany | ||
| 6 | EUCTR2016-004574-17-ES (EUCTR) | 08/06/2017 | 07/04/2017 | A study to measure how safe CC-220 is and how well CC-220 works in people with lupus. | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | SYSTEMIC LUPUS ERYTHEMATOSUS MedDRA version: 19.1;Level: LLT;Classification code 10025134;Term: Lupus erythematosus;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 Product Code: CC-220 INN or Proposed INN: CC-220 Other descriptive name: CC-220 | Celgene Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 280 | Phase 2 | Serbia;United States;Spain;Russian Federation;Colombia;Italy;Hungary;Mexico;Canada;Argentina;Belgium;Brazil;Poland;Germany | ||
| 7 | NCT02185040 (ClinicalTrials.gov) | September 16, 2014 | 7/7/2014 | A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. | A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: CC-220;Drug: Placebo | Celgene | NULL | Completed | 18 Years | N/A | All | 42 | Phase 2 | United States |